Thursday, May 07, 2009 2:10:26 PM
May 7, 2009 2:02:00 PM
Email Story Discuss on ZenoBank
View Additional ProfilesAUBURN HILLS, Mich., May 7 /PRNewswire-FirstCall/ -- Ecology Coatings, Inc. (OTC Bulletin Board: ECOC), a leader in the discovery and development of nanotechnology-enabled, ultraviolet-curable advanced coatings, today announced that its CEO Bob Crockett was interviewed by the Wall Street Reporter's analyst Juan Costello. Shareholders and members of the financial community are invited to listen to Mr. Crockett's interview, which is available for a limited time at www.wallstreetreporter.com .
Mr. Crockett discussed the following topics:
-- The company's recent development agreement with a steel container
company
-- Opportunities and challenges facing the company during 2009
-- Positioning of Ecology Coatings within the coatings industry
-- Overview of Ecology Coatings' products and services
-- Discussion of current projects
-- The company's growth strategy
About Ecology Coatings, Inc.
Ecology Coatings, Inc. (OTC Bulletin Board: ECOC), is a world leader in the development and licensing of cleantech ultra-violet (UV) curable coatings -- coatings that improve the products we use daily. Ecology's technology platform allows manufacturers to enhance the durability and performance of their products, while significantly reducing energy costs and increasing manufacturing throughput. The company produces solid coatings which eliminate the escape of harmful solvents into the atmosphere during application. Headquartered in Auburn Hills, Michigan, Ecology Coatings has a development and prototype lab in Akron, Ohio. For additional information, visit the company's website at http://www.ecologycoatings.com.
Investor and Media Relations
McCloud Communications, LLC
Marty Tullio, Managing Member
949.553.9748
Marty@McCloudCommunications.com
SOURCE Ecology Coatings, Inc.
----------------------------------------------
Marty Tullio
Managing Member of McCloud Communications
LLC
for Ecology Coatings
Inc.
+1-949-553-9748
Marty@McCloudCommunications.com
Recent ABVC News
- AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share • GlobeNewswire Inc. • 04/18/2024 01:25:00 PM
- ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M • GlobeNewswire Inc. • 04/17/2024 01:00:00 PM
- ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M • GlobeNewswire Inc. • 04/10/2024 12:30:00 PM
- ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M • GlobeNewswire Inc. • 03/26/2024 12:30:00 PM
- AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars • GlobeNewswire Inc. • 03/21/2024 12:30:00 PM
- ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine • GlobeNewswire Inc. • 03/19/2024 12:30:00 PM
- ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update • GlobeNewswire Inc. • 03/14/2024 01:30:31 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/29/2024 09:32:35 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/29/2024 09:31:06 PM
- ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars • GlobeNewswire Inc. • 02/27/2024 01:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/16/2024 10:04:42 PM
- ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues • GlobeNewswire Inc. • 02/15/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:59:14 AM
- ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD) • GlobeNewswire Inc. • 02/12/2024 01:30:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/09/2024 10:04:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 02:30:48 PM
- ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share • GlobeNewswire Inc. • 02/08/2024 02:17:05 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/17/2024 10:01:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 10:00:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:30:12 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/12/2024 10:01:27 PM
- ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees • GlobeNewswire Inc. • 01/03/2024 12:24:57 PM
- ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study • GlobeNewswire Inc. • 12/07/2023 01:30:00 PM
- ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials • GlobeNewswire Inc. • 12/05/2023 01:30:00 PM
- ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market • GlobeNewswire Inc. • 11/21/2023 01:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM